Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?

Expert Rev Vaccines. 2015 Mar;14(3):435-46. doi: 10.1586/14760584.2015.979797. Epub 2014 Dec 13.


Cancer vaccine development efforts have recently gained momentum, but most vaccines showing clinical impact in human trials tend to be based on technology approaches that are very costly and difficult to produce at scale. With the projected doubling of the incidence of cancer and its related cost of care in the U.S. over the next two decades, the widespread clinical use of such vaccines will prove difficult to justify. Heat shock protein-based vaccines have shown the potential to elicit clinically meaningful immunologic responses in cancer, but the predominant development approach - heat shock protein-peptide complexes derived from a patient's own tumor - face similar challenges of cost and scalability. New innovative modalities for deploying heat shock proteins in cancer vaccines may open the door to vaccines that can generate potent cytotoxic responses against multiple tumor targets and can be made in a cost-effective and scalable manner.

Keywords: antigen presenting cells; cancer treatment costs; cancer vaccine; heat shock protein; immunotherapy; mesothelioma; ovarian cancer; tumor associated antigens.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / immunology*
  • Bacterial Proteins / genetics
  • Bacterial Proteins / immunology*
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / isolation & purification*
  • HSP70 Heat-Shock Proteins / genetics
  • HSP70 Heat-Shock Proteins / immunology*
  • Humans
  • Neoplasms / therapy
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology*
  • T-Lymphocytes, Cytotoxic / immunology


  • Antigens, Neoplasm
  • Bacterial Proteins
  • Cancer Vaccines
  • HSP70 Heat-Shock Proteins
  • HSP70 protein, Mycobacterium tuberculosis
  • Recombinant Fusion Proteins